Trade-Ideas LLC identified

Bio-Techne

(

TECH

) as a strong and under the radar candidate. In addition to specific proprietary factors, Trade-Ideas identified Bio-Techne as such a stock due to the following factors:

  • TECH has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $19.0 million.
  • TECH has traded 1.9402999999999999136690576051478274166584014892578125 options contracts today.
  • TECH is making at least a new 3-day high.
  • TECH has a PE ratio of 38.
  • TECH is mentioned 1.32 times per day on StockTwits.
  • TECH has not yet been mentioned on StockTwits today.
  • TECH is currently in the upper 20% of its 1-year range.
  • TECH is in the upper 35% of its 20-day range.
  • TECH is in the upper 45% of its 5-day range.
  • TECH is currently trading above yesterday's high.

'Strong and Under the Radar' stocks tend to be worthwhile stocks to watch for a variety of factors including historical back testing and price action. Market technicians refer to such stocks as being in an accumulation phase before a mark-up and peak. Traders and hedge funds have frequently found that these types of stocks continue to build a solid price base and then ultimately spike higher and peak when others 'discover' how good the stock is performing. By leveraging the social discovery aspect of StockTwits we are highlighting stocks that don't currently receive much attention from retail investors, but we suspect may soon garner more attention.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in TECH with the Ticky from Trade-Ideas. See the FREE profile for TECH NOW at Trade-Ideas

More details on TECH:

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic products worldwide. The company operates through three segments: Biotechnology, Clinical Controls, and Protein Platforms. The stock currently has a dividend yield of 1.2%. TECH has a PE ratio of 38. Currently there are 4 analysts that rate Bio-Techne a buy, no analysts rate it a sell, and 1 rates it a hold.

The average volume for Bio-Techne has been 221,300 shares per day over the past 30 days. Bio-Techne has a market cap of $4.0 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.77 and a short float of 5% with 9.68 days to cover. Shares are up 19.1% year-to-date as of the close of trading on Thursday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Bio-Techne as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, expanding profit margins and good cash flow from operations. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity.

Highlights from the ratings report include:

  • TECH's revenue growth has slightly outpaced the industry average of 11.9%. Since the same quarter one year prior, revenues rose by 14.7%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • TECH's debt-to-equity ratio is very low at 0.19 and is currently below that of the industry average, implying that there has been very successful management of debt levels. Along with this, the company maintains a quick ratio of 3.71, which clearly demonstrates the ability to cover short-term cash needs.
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Life Sciences Tools & Services industry. The net income increased by 24.7% when compared to the same quarter one year prior, going from $24.29 million to $30.29 million.
  • The gross profit margin for BIO-TECHNE CORP is currently very high, coming in at 71.42%. Regardless of TECH's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, TECH's net profit margin of 23.12% significantly outperformed against the industry.
  • Net operating cash flow has increased to $37.14 million or 20.66% when compared to the same quarter last year. Despite an increase in cash flow of 20.66%, BIO-TECHNE CORP is still growing at a significantly lower rate than the industry average of 115.36%.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.